Is 20MP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 20MP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 20MP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 20MP's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 20MP?
Key metric: As 20MP barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for 20MP. This is calculated by dividing 20MP's market cap by their current
book value.
What is 20MP's PB Ratio?
PB Ratio
1x
Book
CA$9.24m
Market Cap
CA$8.81m
20MP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: 20MP is good value based on its Price-To-Book Ratio (1x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 20MP's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
20MP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
1x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate 20MP's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.